Takeda eyeing early 2022 rollout of Novavax's COVID-19 shot in Japan - CEO

Takeda Pharmaceutical Co, the Japanese partner for Novavax Inc's COVID-19 vaccine, is preparing to seek regulatory approval for a roll out in Japan early next year, its top executive said on Friday. Novavax delayed filing for U.S. approval to the end of this year, and Politico reported this month that the Maryland-based company has faced production and quality problems. The drugmaker filed for conditional authorisation to British regulators on Wednesday and with Australia's Therapeutic Goods Administration on Friday